BRCA1 and cancer: To determine whether NVB would activate the cGAS/STING pathway in HR-deficient cancers in vivo, we performed flow cytometric analysis of both Brca1-deficient TNBC tumors and Brca2-deficient PDAC tumors from immunocompetent mice treated for 5 days with NVB.